The share of Americans using glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss has surged to unprecedented levels, according to reports on rising demand and market forecasts. A new analysis from Goldman Sachs projects the global anti-obesity drug market will reach $114 billion by 2030, up from a prior estimate of $101 billion, driven by faster adoption of oral obesity pills and improved affordability, according to analysts Asad Haider and James Quigley [1].
Multiple reports indicate that the number of patients taking medications such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound) has climbed sharply as insurers and government programs expand coverage. ChildrensHealthDefense.org reported that demand for these drugs has skyrocketed, with clinicians observing a parallel increase in reports of side effects ranging from mild digestive issues to more severe gastrointestinal complications, self-harm behavior, and cancer [2]. The rapid uptake signals a fundamental shift in how obesity is being managed, moving from lifestyle-focused approaches toward pharmaceutical intervention.
Read Full Article: https://www.naturalnews.com/2026-07-09-glp1-use-reaches-record-high-as-access-broadens.html
